NO20031580L - Fremgangsmåter for modulering av bl¶refunksjonen - Google Patents

Fremgangsmåter for modulering av bl¶refunksjonen

Info

Publication number
NO20031580L
NO20031580L NO20031580A NO20031580A NO20031580L NO 20031580 L NO20031580 L NO 20031580L NO 20031580 A NO20031580 A NO 20031580A NO 20031580 A NO20031580 A NO 20031580A NO 20031580 L NO20031580 L NO 20031580L
Authority
NO
Norway
Prior art keywords
modulating
procedures
bleeding function
bleeding
function
Prior art date
Application number
NO20031580A
Other languages
English (en)
Other versions
NO20031580D0 (no
Inventor
Michael Thomas Argentieri
Howard Jeffrey Sheldon
Robert Mark Bowlby
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031580(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20031580D0 publication Critical patent/NO20031580D0/no
Publication of NO20031580L publication Critical patent/NO20031580L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/341—Urinary incontinence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20031580A 2000-10-17 2003-04-08 Fremgangsmåter for modulering av bl¶refunksjonen NO20031580L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24107800P 2000-10-17 2000-10-17
US28142801P 2001-04-04 2001-04-04
PCT/US2001/032204 WO2002032419A2 (en) 2000-10-17 2001-10-16 Methods for modulating bladder function

Publications (2)

Publication Number Publication Date
NO20031580D0 NO20031580D0 (no) 2003-04-08
NO20031580L true NO20031580L (no) 2003-06-14

Family

ID=26933980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031580A NO20031580L (no) 2000-10-17 2003-04-08 Fremgangsmåter for modulering av bl¶refunksjonen

Country Status (22)

Country Link
US (3) US6348486B1 (no)
EP (2) EP1326597B1 (no)
JP (2) JP2004511516A (no)
KR (1) KR20030040540A (no)
CN (1) CN1287781C (no)
AR (1) AR030901A1 (no)
AT (1) ATE314061T1 (no)
AU (2) AU2002211758A1 (no)
BR (1) BR0114718A (no)
CA (2) CA2450467C (no)
CY (1) CY1105353T1 (no)
DE (1) DE60116352T2 (no)
DK (1) DK1326597T3 (no)
ES (1) ES2253432T3 (no)
HU (1) HUP0303288A2 (no)
IL (1) IL155090A0 (no)
MX (1) MXPA03003339A (no)
NO (1) NO20031580L (no)
NZ (1) NZ525301A (no)
PL (1) PL360903A1 (no)
TW (1) TWI287984B (no)
WO (2) WO2002032419A2 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
KR20050074493A (ko) * 2002-10-21 2005-07-18 라모트 앳 텔-아비브 유니버시티 리미티드 칼륨 채널 및/또는 피질 뉴우런 작용 조절제로서 유용한ｎ-페닐안트라닐산 및/또는 2-벤즈이미다졸론의 유도체
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2004233941A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20070292528A1 (en) * 2003-05-06 2007-12-20 University Hospital Of Basel Kcnma1 as a Therapeutic Target in Cancer Treatment
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US7517960B2 (en) 2006-01-19 2009-04-14 Wyeth Rat KCNQ5 voltage-gated potassium channel
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
WO2008024398A2 (en) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
DE102007012029A1 (de) 2007-03-13 2008-09-18 Grünenthal GmbH Verfahren zur Identifizierung der agonistischen Aktivität einer Zielverbindung auf einen Kaliumkanal
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (en) * 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
DK3085381T3 (en) * 2008-05-21 2018-05-28 Ferring Bv ORODISPERSIBLE DESMOPRESSIN TO INCREASE THE INITIAL PERIOD OF SLEEP UNDERSTANDED BY NEW TURRY
MX2011000636A (es) * 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Formulacion de liberacion modificada y metodos de uso.
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011101456A2 (en) * 2010-02-19 2011-08-25 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
AU2013257209B2 (en) 2012-04-30 2016-05-19 Scifluor Life Sciences, Inc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
JP7780440B2 (ja) * 2019-10-07 2025-12-04 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素二環式化合物
AU2020363354A1 (en) * 2019-10-07 2022-04-21 D.E. Shaw Research, Llc Aryl heterobicyclic compounds as Kv1.3 potassium shaker channel blockers
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
GEP20257732B (en) 2019-11-08 2025-02-10 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
KR20240004241A (ko) 2021-02-09 2024-01-11 제논 파마슈티칼스 인크. 무쾌감증의 치료에 사용하기 위한 전압-게이트 칼륨 채널 오프너
WO2025233532A1 (en) 2024-05-10 2025-11-13 Les Laboratoires Servier Maxi-k potassium channel openers and therapeutic applications thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37460A (en) * 1863-01-20 Improvement in meat-broilers
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
EP1007638B1 (en) 1997-08-12 2007-03-07 Bristol-Myers Squibb Company Kcnq potassium channels and methods of modulating same
JP4520634B2 (ja) * 1997-10-24 2010-08-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 良性の家族性新生児痙攣（ｂｆｎｃ）および他の癲癇において突然変異されたｋｃｎｑ２およびｋｃｎｑ３−カリウムチャンネル遺伝子
WO1999041372A1 (en) * 1998-02-17 1999-08-19 Astrazeneca Uk Limited Potassium channel polypeptide
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6794161B1 (en) 1999-01-26 2004-09-21 Neurosearch A/S Potassium channels and genes encoding these potassium channels
DK1147134T3 (da) * 1999-01-26 2007-02-05 Neurosearch As Hidtil ukendte kaliumkanaler og gener, der koder for disse kaliumkanaler
IT1312224B1 (it) * 1999-03-23 2002-04-09 Cit Alcatel Circuito pre/post-distorcitore particolarmente per sistemi aradiofrequenza microonde.
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6617131B2 (en) * 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
JP2004505610A (ja) * 2000-04-03 2004-02-26 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトイオンチャンネルタンパク質およびそれをコードするポリヌクレオチド
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6613786B2 (en) * 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
EP1583821A4 (en) * 2003-01-15 2007-07-18 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
US20070021391A1 (en) * 2003-06-30 2007-01-25 Takayuki Doi Preventive/remedy for urinary disturbance
JP4977837B2 (ja) * 2003-09-10 2012-07-18 アイカジェン， インコーポレイテッド カリウム・チャネル・モジュレーターとしての縮合環式複素環
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
US7517960B2 (en) * 2006-01-19 2009-04-14 Wyeth Rat KCNQ5 voltage-gated potassium channel

Also Published As

Publication number Publication date
JP2004529611A (ja) 2004-09-30
AR030901A1 (es) 2003-09-03
DE60116352D1 (de) 2006-02-02
WO2002032419A2 (en) 2002-04-25
NO20031580D0 (no) 2003-04-08
EP1326597B1 (en) 2005-12-28
WO2002032960A3 (en) 2003-04-17
DK1326597T3 (da) 2006-02-13
WO2002032419A3 (en) 2002-08-15
AU2002211758A1 (en) 2002-04-29
BR0114718A (pt) 2003-10-14
PL360903A1 (en) 2004-09-20
JP2004511516A (ja) 2004-04-15
NZ525301A (en) 2004-10-29
ES2253432T3 (es) 2006-06-01
MXPA03003339A (es) 2003-06-19
IL155090A0 (en) 2003-10-31
DE60116352T2 (de) 2006-06-22
HK1056514A1 (en) 2004-02-20
US20060252104A1 (en) 2006-11-09
CN1287781C (zh) 2006-12-06
HUP0303288A2 (hu) 2004-01-28
KR20030040540A (ko) 2003-05-22
EP1328550A2 (en) 2003-07-23
WO2002032960A2 (en) 2002-04-25
ATE314061T1 (de) 2006-01-15
US6348486B1 (en) 2002-02-19
US7160684B2 (en) 2007-01-09
CN1469739A (zh) 2004-01-21
CA2450467A1 (en) 2002-04-25
EP1326597A2 (en) 2003-07-16
TWI287984B (en) 2007-10-11
CA2425742A1 (en) 2002-04-25
CY1105353T1 (el) 2010-03-03
AU2002213308A1 (en) 2002-04-29
CA2450467C (en) 2011-05-24
US20050101004A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
NO20031580D0 (no) Fremgangsmåter for modulering av bl¶refunksjonen
DE60141776D1 (de) Trokaranordnung
DE59808818D1 (de) Chirurgischer Spreizer
FI20001774L (fi) Lähetinvastaanottimen testaaminen
BR7903354Y1 (pt) dispositivo de apresentaÇço.
DE60142401D1 (de) Verbindungsverfahren
MXPA01011760A (es) Compuestos novedosos de difeniletileno.
ES1046206Y (es) Aparato quirurgico.
EP1315423A4 (en) THERMOSTABLE BIOLOGICAL MATRIX
DE60032221D1 (de) Trokarsystem
DE60041783D1 (de) Bremseinheit
NO20022363L (no) Tannimplantatb¶rersammenstilling
ATA4432000A (de) Streugerät
NO20031941D0 (no) Diagnostisk fremgangsmåte
DE50106006D1 (de) Streugerät
EP1307662A4 (en) Brake plate
DE60115145D1 (de) Elektrochirurgisches System
DK1102012T3 (da) Udluftningsindretning
DE50007351D1 (de) Zweischeibenschleuderstreuer
ATA80062000A (de) Spreizvorrichtung
ES1047885Y (es) Aplique luminoso polivalente.
NO20005126D0 (no) FremgangsmÕte for formidling av informasjon
NO20032603L (no) Fremgangsmate for transaksjonsstyring
FI20000743A0 (fi) Vetopuomi
FIU20000440U0 (fi) Metsäkone

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application